Literature DB >> 27225242

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.

Curtis Cooper1, Susanna Naggie2, Michael Saag3, Jenny C Yang4, Luisa M Stamm4, Hadas Dvory-Sobol4, LingLing Han4, Phillip S Pang4, John G McHutchison4, Douglas Dieterich5, Mark Sulkowski6.   

Abstract

UNLABELLED: We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. CLINICAL TRIALS REGISTRATION: NCT02073656.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  HCV NS5B polymerase inhibitor; HCV/HIV coinfection; NS5A resistance; direct-acting antiviral agents; re-treatment

Mesh：

Substances：

Year:  2016        PMID： 27225242      PMCID： PMC4967607          DOI： 10.1093/cid/ciw349

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  16 in total

1.  Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.

Authors:  Eric G Meissner; David Wu; Anu Osinusi; Dimitra Bon; Kimmo Virtaneva; Dan Sturdevant; Steve Porcella; Honghui Wang; Eva Herrmann; John McHutchison; Anthony F Suffredini; Michael Polis; Stephen Hewitt; Ludmila Prokunina-Olsson; Henry Masur; Anthony S Fauci; Shyamasundaran Kottilil
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

2.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

Review 3.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

4.  Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.

Authors:  Michael W Fried; Joy Peter; Keith Hoots; Paul J Gaglio; Donald Talbut; P Charleton Davis; Nigel S Key; Gilbert C White; Lauren Lindblad; Frederick R Rickles; Thomas C Abshire
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

5.  Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.

Authors:  Saleh A Alqahtani; Nezam Afdhal; Stefan Zeuzem; Stuart C Gordon; Alessandra Mangia; Paul Kwo; Michael Fried; Jenny C Yang; Xiao Ding; Phillip S Pang; John G McHutchison; David Pound; K Rajender Reddy; Patrick Marcellin; Kris V Kowdley; Mark Sulkowski
Journal:  Hepatology       Date:  2015-06-01       Impact factor: 17.425

6.  Ribavirin improves early responses to peginterferon through improved interferon signaling.

Authors:  Jordan J Feld; Glen A Lutchman; Theo Heller; Koji Hara; Julie K Pfeiffer; Richard D Leff; Claudia Meek; Maria Rivera; Myung Ko; Christopher Koh; Yaron Rotman; Marc G Ghany; Vanessa Haynes-Williams; Avidan U Neumann; T Jake Liang; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2010-03-17       Impact factor: 22.682

7.  The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

Authors:  Sifang Zhou; Rong Liu; Bahige M Baroudy; Bruce A Malcolm; Gregory R Reyes
Journal:  Virology       Date:  2003-06-05       Impact factor: 3.616

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production.

Authors:  Yang Wang; David R McGivern; Liang Cheng; Guangming Li; Stanley M Lemon; Junqi Niu; Lishan Su; Natalia J Reszka-Blanco
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

10.  Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.

Authors:  Jun Itakura; Masayuki Kurosaki; Mayu Higuchi; Hitomi Takada; Natsuko Nakakuki; Yoshie Itakura; Nobuharu Tamaki; Yutaka Yasui; Shoko Suzuki; Kaoru Tsuchiya; Hiroyuki Nakanishi; Yuka Takahashi; Shinya Maekawa; Nobuyuki Enomoto; Namiki Izumi
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240
View more
  5 in total

Review 1.  Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.

Authors:  Eric G Meissner
Journal:  Curr Opin Gastroenterol       Date:  2017-05       Impact factor: 3.287

Review 2.  Remaining clinical issues in hepatitis C treatment.

Authors:  Alexander Wong; Cynthia Tsien; Sarah Mansour; Curtis Cooper
Journal:  Can Liver J       Date:  2018-07-17

3.  Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.

Authors:  Dorota Zarębska-Michaluk; Iwona Buczyńska; Krzysztof Simon; Magdalena Tudrujek-Zdunek; Ewa Janczewska; Dorota Dybowska; Marek Sitko; Beata Dobracka; Jerzy Jaroszewicz; Paweł Pabjan; Jakub Klapaczyński; Łukasz Laurans; Włodzimierz Mazur; Łukasz Socha; Olga Tronina; Miłosz Parczewski; Robert Flisiak
Journal:  Can J Gastroenterol Hepatol       Date:  2019-03-03

Review 4.  Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2018-02       Impact factor: 11.431

Review 5.  Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.

Authors:  Thomas F Baumert; Frank Jühling; Atsushi Ono; Yujin Hoshida
Journal:  BMC Med       Date:  2017-03-14       Impact factor: 11.150
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.